Estazolam Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are reporting difficulty filling Estazolam prescriptions, their experience reflects a broader supply challenge affecting this benzodiazepine. While Estazolam may not always appear on formal FDA or ASHP shortage lists, its limited manufacturing base and low production volumes create persistent access barriers that clinicians need to understand and plan around.

This briefing covers the current supply landscape, prescribing implications, therapeutic alternatives, and tools to help both you and your patients navigate Estazolam availability in 2026.

Supply Timeline and Background

Estazolam (formerly branded as ProSom) is a triazolobenzodiazepine with an intermediate half-life of 10-24 hours, FDA-approved for the short-term treatment of insomnia. The brand-name product was discontinued years ago, leaving the U.S. market entirely dependent on generic production.

Key supply milestones:

• 2016: The FTC documented that only two manufacturers — Allergan and Teva — supplied all generic Estazolam (1 mg and 2 mg tablets) in the U.S. market, raising antitrust concerns during the Teva-Allergan acquisition review.
• 2016-2024: The manufacturer base remained limited. Par Pharmaceutical (Endo) entered or maintained supply alongside Teva, but production volumes stayed low relative to other benzodiazepines.
• 2025-2026: Estazolam is not formally listed on FDA/ASHP shortage databases, but pharmacies across the country report inconsistent availability. The drug appears to be in a state of functional undersupply — technically manufactured, but not reliably accessible at the point of dispensing.

Prescribing Implications

The practical scarcity of Estazolam has several implications for prescribers:

Patient Compliance and Continuity

Patients who have been stabilized on Estazolam may experience gaps in therapy when their pharmacy can't fill the prescription. This is particularly concerning because:

• Abrupt discontinuation of benzodiazepines can trigger withdrawal symptoms including anxiety, insomnia rebound, tremor, and in severe cases, seizures
• Patients may seek the medication from unreliable sources if they can't fill their prescription through legitimate channels
• Repeated fill failures erode patient trust and medication adherence

Controlled Substance Considerations

As a Schedule IV controlled substance, Estazolam prescriptions face additional hurdles:

• Patients cannot simply transfer prescriptions between pharmacies in all states
• Refill timing restrictions (typically 2-3 days early maximum) limit the buffer patients can maintain
• DEA manufacturing quotas may constrain total annual production
• Some pharmacies have internal policies restricting controlled substance orders

Documentation and Communication

When prescribing Estazolam, consider proactively documenting the clinical rationale for this specific agent versus alternatives. This can expedite insurance authorization processes and support patients who need to work with multiple pharmacies to find stock.

Current Availability Picture

The availability of Estazolam varies significantly by geography, pharmacy type, and timing:

• Chain pharmacies (CVS, Walgreens, Rite Aid) may be less likely to stock Estazolam due to lower demand and centralized inventory management
• Independent pharmacies often have more flexibility with distributors and may maintain supply
• Hospital and institutional pharmacies may have limited stock depending on formulary decisions
• Mail-order pharmacies may have better access through centralized distribution but face state-specific controlled substance regulations

Tools like Medfinder for Providers can help your practice identify pharmacies with current Estazolam availability in your patients' areas.

Cost and Access Considerations

Cost remains a factor for many patients, especially those without comprehensive prescription coverage:

• Average retail price: ~$158 for 30 tablets (without insurance or coupons)
• Discount coupon price: $25-$30 for 30 tablets via GoodRx, SingleCare
• Medicare Part D: Most plans do not cover benzodiazepines for insomnia — a critical point to discuss with Medicare-age patients
• No manufacturer savings program: With ProSom discontinued, there is no branded copay assistance available
• Patient assistance: No dedicated manufacturer PAP. Patients may be directed to NeedyMeds or RxAssist for general assistance resources

For patients struggling with costs, our savings guide for Estazolam provides detailed pricing information.

Therapeutic Alternatives

When Estazolam is unavailable, the following alternatives warrant consideration based on the patient's clinical profile:

Benzodiazepine Alternatives

• Temazepam (Restoril): Most pharmacologically similar. Intermediate half-life (8-15 hours). FDA-approved for insomnia. Widely available. Typical dose: 15-30 mg at bedtime.
• Triazolam (Halcion): Short-acting triazolobenzodiazepine in the same subclass. Half-life 1.5-5.5 hours. Best for sleep-onset insomnia. Typical dose: 0.125-0.25 mg.

Non-Benzodiazepine Alternatives

• Zolpidem (Ambien/Ambien CR): GABA-A receptor agonist with more selective binding. Multiple formulations available. Very widely available. Typical dose: 5-10 mg IR or 6.25-12.5 mg ER.
• Suvorexant (Belsomra): Dual orexin receptor antagonist. Different mechanism with lower dependence risk. Typical dose: 10-20 mg. Significantly more expensive (brand only).
• Lemborexant (Dayvigo): Newer DORA with favorable safety profile. Typical dose: 5-10 mg.
• Low-dose Doxepin (Silenor): Histamine H1 antagonist at low doses. 3-6 mg. Effective for sleep maintenance insomnia.

Dose equivalence should be individualized. When transitioning from Estazolam, consider cross-tapering rather than abrupt switching to minimize withdrawal risk. For more on alternatives, our alternatives guide provides patient-friendly information you can share.

Tools and Resources for Your Practice

• Medfinder for Providers: Real-time pharmacy stock search to help locate Estazolam and other hard-to-find medications for your patients
• ASHP Drug Shortages Center: Monitor for formal shortage listings and updates
• FDA Drug Shortages Database: Check for current FDA-tracked shortages and expected resolution dates
• State PDMP (Prescription Drug Monitoring Program): Verify patient fill history when coordinating care across pharmacies

Looking Ahead

Estazolam's supply challenges are structural. With only two to three manufacturers serving the entire U.S. market, a discontinued brand, and declining prescribing rates, the medication is unlikely to see significant supply improvement without new market entrants or policy changes.

Clinically, the trend in insomnia treatment is moving away from benzodiazepines and toward newer agents (DORAs, low-dose doxepin) and cognitive behavioral therapy for insomnia (CBT-I). For patients currently maintained on Estazolam, continuity of care remains the priority — but for new insomnia patients, prescribers may want to consider agents with more reliable supply chains and lower regulatory burden.

Final Thoughts

Estazolam remains a clinically appropriate option for short-term insomnia treatment, but its supply limitations create real challenges for patient care. Proactive communication with patients about potential availability issues, familiarity with therapeutic alternatives, and utilization of tools like Medfinder for Providers can help your practice navigate these challenges effectively.

For additional provider resources, see our companion guide on how to help your patients find Estazolam in stock.